Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 17/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140219 | 0.84 | WDR5 (0.50) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL4824126 | 0.79 | SIRT6 (0.65) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL4831177 | 0.79 | TNF (0.64) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL20214038 | 0.78 | WDR5 (1.00) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL8829646 | 0.77 | ALDH1A1 (0.55) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL6978611 | 0.77 | MAPK14 (0.59) | — | |
| SCHEMBL27763626 | 0.77 | ALDH1A1 (0.52) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL4832961 | 0.76 | SIRT6 (0.61) | WDR5ALDH1A1CYP2D6KMT2AMEN1 | |
| SCHEMBL4831687 | 0.75 | HPGDS (0.54) | WDR5ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL20213949 | 0.75 | WDR5 (1.00) | WDR5ALDH1A1CYP2D6KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| CN-1178932-C | Amide derivatives | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1350530-A | Amide derivatives | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | WDR5 4637/4885ALDH1A1 269/4885CYP2D6 35/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | WDR5 4637/4885ALDH1A1 269/4885CYP2D6 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.